Article
Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
The American journal of gastroenterology - 1 Nov 2005
El-Zayadi Abdel-Rahman, Attia Mohy, Barakat Eman M F, Badran Hanaa M, Hamdy Hassan, El-Tawil Ahmed, El-Nakeeb Adham, Selim Osaima, Saied Ahmed
Abstract excerpt
BACKGROUND AND AIM: Currently, pegylated interferon is the most effective therapy for hepatitis C but its cost is out of reach of most patients in the developing countries. The aim of this study was to assess the response rate of genotype-4 patients to 24 wks of peg-interferon-alpha2b (Peg-IFN-alpha2b) and ribavirin (RBV) or interferon-alpha2b (IFN-alpha2b) with RBV and amantadine (AMD) as an alternative option....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.